Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AT1 blocker candesartan · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Candesartan | ACTIVE_COMPARATOR | Candasartan |
| Name | Type | Description |
|---|---|---|
| AT1 blocker candesartan | DRUG | AT1 blocker candesartan, 32 mg oral QD |
| Placebo | DRUG | Placebo, 32 mg, oral QD |
Inclusion Criteria: * Women aged ≥18 years * WHO: ≤ 2 * Strongly HER2-positive breast cancer, defined as an immunohistochemistry score of 3+ using the HercepTestTM, or gene amplification by fluorescence in situ hybridization, or chromogenic in situ hybridization (CISH). * Serum creatinine \<140 umo...
Top 20 of 92 competitors
AT1 blocker candesartan is an investigational small molecule being studied in breast cancer. It is being evaluated in a Phase 3 clinical trial for the prevention of trastuzumab-associated cardiotoxicity in breast cancer patients. The drug is an angiotensin II receptor blocker, also known as an AT1 blocker.
AT1 blocker candesartan targets the angiotensin II type 1 receptor, also known as the AT1 receptor. By blocking this receptor, the drug may help prevent cardiotoxicity associated with trastuzumab treatment in breast cancer patients. The mechanism is being studied in a Phase 3 clinical trial.
AT1 blocker candesartan is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The drug is currently in Phase 3 clinical development for breast cancer, specifically for the prevention of trastuzumab-associated cardiotoxicity.
AT1 blocker candesartan is in Phase 3 clinical development. It is an investigational drug, not yet approved, and is being studied for the prevention of trastuzumab-associated cardiotoxicity in breast cancer patients. The Phase 3 trial has been completed.
AT1 blocker candesartan has one completed Phase 3 clinical trial, identified as NCT00459771. The trial, titled 'Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity,' enrolled 210 female breast cancer patients in the Netherlands. The study was randomized, double-blind, and placebo-controlled.
Yes, AT1 blocker candesartan is the same as candesartan. The drug is an angiotensin II receptor blocker, commonly referred to as an AT1 blocker. In the clinical trial context, it is being studied under the name candesartan for its potential to prevent trastuzumab-associated cardiotoxicity in breast cancer patients.